Evidence map›Paper›PMID 30120213›Full record

ArticleJournal of medical genetics2019

Global microarray profiling identified

Qiaoyou Weng, Minjiang Chen, Maoquan Li, Yong-Fa Zheng, Guoliang Shao, Weijun Fan, Xi-Ming Xu, Jiansong Ji

RetractedAbstract readRetracted Publication
PubMed Publisher
In one paragraph

Article in Journal of medical genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Qiaoyou Weng *Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Affiliated Lishui Hospital of Zhejiang University/The Fifth Affiliated Hospital of Wenzhou Medical University/The Central Hospital of Zhejiang Lishui, Lishui, China.
Minjiang Chen *Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Affiliated Lishui Hospital of Zhejiang University/The Fifth Affiliated Hospital of Wenzhou Medical University/The Central Hospital of Zhejiang Lishui, Lishui, China.
Maoquan LiDepartment of Interventional and Vascular Surgery, The Tenth People's Hospital of Shanghai, Tongji University, Shanghai, China.
Yong-Fa ZhengCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Guoliang ShaoDepartment of Radiology, The Cancer Hospital of Zhejiang Province, Hangzhou, China.
Weijun FanMedical Imaging Center, Sun Yat-sen University Cancer Center, Guangzhou, China.
Xi-Ming XuCancer Center, Renmin Hospital of Wuhan University, Wuhan, China.
Jiansong JiKey Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, Affiliated Lishui Hospital of Zhejiang University/The Fifth Affiliated Hospital of Wenzhou Medical University/The Central Hospital of Zhejiang Lishui, Lishui, China.ORCID 0000-0003-4727-2794
Wenzhou Medical University · CNWuhan University · CNSun Yat-sen University · CNTongji University · CNZhejiang Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIncreasing evidence has shown that circular RNAs (circRNAs) are involved tumourigenesis and metastasis of hepatocellular carcinoma (HCC); however, progression about its function in HCC is relatively slow. Here, we aimed to investigate whether plasma circRNAs could reflect the tumour-infiltrating lymphocytes (TILs) in HCC tumour tissues and serve as prognosis biomarker for HCC.

methodsTissue samples of patients with HCC were subjected to immunohistochemistry staining against CD8 to examine the TILs. Then, we investigated the expression profile of circRNAs by microarray between plasma of patients with HCC with high TILs and low TILs, and the differentially expressed circRNAs were validated with qRT-PCR. Statistical analysis was performed with SPSS software and GraphPad Prism.

resultsWe have demonstrated that patients with HCC with high TILs exhibit a significant better overall survival, suggesting clinical outcome could be predicted by TILs. Global circRNA microarray between plasma of patients with HCC with high TILs and low TILs successfully identified six differentially expressed novel circRNAs. Among them, the expression of

conclusionThese findings together imply that

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularComputational BiologyFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansImmunohistochemistryLiver NeoplasmsLymphocyte CountLymphocytes, Tumor-InfiltratingMaleNeoplasm StagingPrognosisReproducibility of ResultsRNA, CircularBiomarkers, TumorRNA, Circularcircular rnashepatocellular carcinomahsa_circ_0064428tumor infiltrating lymphocytes

Identifiers

PMID30120213
OpenAlexW2887473218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.